CA215 and GnRH receptor as targets for cancer therapy

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1805-1817

  Lee, Gregory ^a   Cheung, Anthony P ^a   Ge, Bixia ^a   Zhu, Mingang ^a   Giolma, Brett ^a   Li, Bo ^a   Wong, Eric ^a   Li, Yu ^b   Wang, Yu ^b   Chen, Zinan ^b   Gu, Jiang ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

CA215; Carbohydrate associated epitope(s); GHR106; GnRH receptor; Immunoglobulin superfamily proteins; RP215

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; GEMCITABINE; GLYCOPROTEIN; GONADORELIN RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN SUPERFAMILY PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GHR106; MONOCLONAL ANTIBODY RP215; MUCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LOW DRUG DOSE; LUNG SQUAMOUS CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CA-125 ANTIGEN; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASMS; RECEPTORS, LHRH; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867577134     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1230-8     Document Type: Article

References (29)

1. Monoclonal Antibodies. American Cancer Society. http://www. cancer.org/Treatment/TreatmentsandSideEffects/TreatmentTypes/Immunotherapy/ immunotherapy-monoclonal-Antibodies (accessed November 2010)
2. Cancer Research UK. http://www.cancerresearchuk.org/aboutcancer/ specificcancers/prostatecancer (accessed December 2004)
3. Garnick MB, Fair WR (1998) Combating prostate cancer. Sci Am 279:74-83
4. Lee G, Laflamme E, Chien CH, Ting HH (2008) Molecular identity of a pan cancer marker, CA215. Cancer Biol Ther 7:2007-2014
5. Lee G, Ge B (2009) Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-Associated biomarker. Cancer Biomark 5:177-188
6. Lee G, Ge B (2010) Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor. Cancer Immunol Immunother 59:1011-1019
7. Lee G, Wu Q, Li CH, Ting HH, Chien CH (2006) Recent studies of a new carbohydrate-Associated pan cancer marker, CA215. J Clin Ligand Assay 29:47-51
8. Lee G, Chu RA, Ting HH (2009) Preclinical assessment of anticancer drugs by using RP215 monoclonal antibody. Cancer Biol Ther 8:161-162
9. Lee G, Zhu M, Ge B (2012) Potential monoclonal antibody therapy for the treatment of ovarian cancer. In: Ovarian cancer - basic science perspective, chap 19. InTech-Open Access Publisher, Rijeka, pp 385-406
10. Lee G, Zhu M, Ge B, Potzold S (2012) Widespread expressions of immunoglobulin superfamily proteins in cancer cells. Cancer Immunol Immunother 61:89-99
11. Mishra A, Verma M (2010) Cancer biomarkers: are we ready for the prime time? Cancers 2:190-208
12. Boyce EA, Kohn EC (2005) Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. Int J Gynecol Cancer 15:266-273
13. Helleman J, Van Der Vlies D, Jansen MPHM, Luider TM, Van Der Burg MEL, Stoter G, Berns EMJJ (2008) Serum proteomic patterns for ovarian cancer monitoring. Int J Gynecol Cancer 18:985-995
14. Annunziata CM, Azad N, Dhamoon AS, Whiteley G, Kohn EC (2008) Ovarian cancer in the proteomics era. Int J Gynecol Cancer 18(Suppl. 1):1-6
15. Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S et al (2010) Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrixassisted laser desorption/ionization time-of-flight mass spectrometry profiling. Int J Gynecol Cancer 20:1518-1524
16. Qiu X, Zhu X, Zhang L, Mao Y, Zhang J, Hao P et al (2003) Human epithelial cancers secrete immunoglobulin G with unidentified specificity to promote growth and survival of tumor cells. Cancer Res 63:6488-6495
17. Hu D, Duan Z, Li M, Jiang Y, Liu H, Zheng H, Li L, Bode AM, Dong Z, Cao Y (2011) Heterogeneity of aberrant immunoglobulin expression in cancer cells. Cell Mol Immun 8:479-485
18. Lee G (2009) Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its diagnostic applications. Cancer Biomarkers 5:137-142
19. Chen A, Kaganovsky E, Rahimipour S, Ben-Aroya N, Okon E, Koch Y (2002) Two forms of gonadotropin-releasing hormone (GnRH) are expressed in human breast tissue and overexpressed in breast cancer: a putative mechanism for the antiproliferative effect of GnRH by down-regulation of acidic ribosomal phosphoproteins P1 and P2. Cancer Res 62:1036-1044
20. Arlaud GJ, Gaboriaud C, Thielens NM, Budayova-Spano M, Rossi V, Fontecilla-Camps JC (2002) Structural biology of the C1 complex of complement unveils the mechanisms of its activation and proteolytic activity. Mol Immunol 39:383-394
21. Cooper NR (1985) The classical complement pathway. Activation and regulation of the first complement component. Adv Immunol 37:151-216
22. Kang SK, Choi K-C, Yang H-S, Leung PCK (2003) Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer. Endocr Relat Cancer 10:169-177
23. So W-K, Cheng J-C, Poon S-L, Leung PCK (2008) Gonadotrophin- releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J 275:5496-5511
24. Emons G, Gruendker C, Guenthert AR, Westphalen S, Kavanagh J, Verschraegen C (2003) GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 10: 291-299
25. Lee G, Chen KW, Sheu FS, Tsang A, Chao KC, Ng HT (1992) Studies of a tumor-Associated antigen, COX-1, recognized by a monoclonal antibody. Cancer Immunol Immunother 35:19-26
26. Liu MS, Aebersold R, Fann CH, Lee CY (1992) Molecular and developmental studies of a sperm acrosome antigen recognized by HS-63 monoclonal antibody. Biol Reprod 46:937-948
27. Lee G, Ge B (2010) Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its antiidiotype antibodies. Cancer Immunol Immunother 59:1347-1356
28. Griffioen M, van Egmond EH, Kester MG, Willemze R, Falkenburg JH, Heemskerk MH (2009) Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 94:1316-1320
29. Zhao X, Singh S, Pardoux C, Zhao J, Hsi ED, Abo A et al (2010) Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 95:71-78